Back to mobile site

Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald on ARO-MAPT Ph1 Data

October 15, 2026 7:57 AM EDT Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented, "ARWR reported positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login